Stocks News

LAST PRICE
135.1000
TODAY'S CHANGE (%)
Trending Down-2.3500 (-1.7097%)

Bid / Lots
131.7200/ 1
Ask / Lots
142.1900/ 1
Open / Previous Close
139.4700 / 137.4500
Day Range
Low 134.8450
High 143.7600
52 Week Range
Low 83.7500
High 161.0000
Volume
587,045
average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Today
- European Equities Traded in US as American Depositary Receipts Rise Friday, Poised to End Week Lower, from 7 hours ago by MT Newswires
  7 hours ago by MT Newswires
  Companies Mentioned: TTE, TRIB, NGG, SQNS, TRVG, VRNA, NCNA, GNFT, AKTX, BNTX, DBVT, CRH, ASND, CLLS, ADAP, BDRX
  11:11 AM EDT, 05/31/2024 (MT Newswires) -- European equities traded in the US as American depositary receipts rose Friday morning, gaining 0.61% to 1,418.20 on the S&P Europe Select ADR Index. The index is poised to end the week lower. From continen...
- Stifel Initiates Ascendis Pharma at Buy Rating With $200 Price Target, from 9 hours ago by MT Newswires
  9 hours ago by MT Newswires
  Companies Mentioned: ASND
  09:26 AM EDT, 05/31/2024 (MT Newswires) -- Ascendis Pharma A/S (ASND) has an average outperform rating and a price target range of $139.68 to $265.55, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic re...
- DJ Ascendis Pharma Initiated at Buy by Stifel, from 12 hours ago by Dow Jones
  12 hours ago by Dow Jones
  Companies Mentioned: ASND
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/ASND/analyst-ratings
  
  (END) Dow Jones Newswires
  
  May 31, 2024 06:14 ET (10:14 GMT)
Yesterday
- Ascendis to Spotlight Latest Updates for TransCon(TM) Rare Endocrinology Disease Portfolio at ENDO 2024, from 8:30AM ET on Thursday May 30, 2024 by Dow Jones
  8:30AM ET on Thursday May 30, 2024 by Dow Jones
  Companies Mentioned: ASND
  
  Ascendis to Spotlight Latest Updates for TransCon(TM) Rare Endocrinology Disease Portfolio at ENDO 2024
  
  COPENHAGEN, Denmark, May 30, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it will host informational booths, events, and presentations showcasing use of its innovative TransCon technology in the areas of growth hormone deficiency (GHD), hypoparathyroidism, achondroplasia, and Turner syndrome during ENDO 2024, the annual meeting of the Endocrine Society being held June 1-4, 2024, in Boston.
May 22, 2024
- European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading, from 11:01AM ET on Wednesday May 22, 2024 by MT Newswires
  11:01AM ET on Wednesday May 22, 2024 by MT Newswires
  Companies Mentioned: FMS, GSK, TRIB, SQNS, GRFS, TRVG, VRNA, GNFT, MREO, BCYC, BNTX, BHP, SLN, EVAX, ASND, BDRX
  11:01 AM EDT, 05/22/2024 (MT Newswires) -- European equities traded in the US as American depositary receipts fell Wednesday morning, declining 0.48% to 1,423.09 on the S&P Europe Select ADR Index. From continental Europe, the gainers were led by bi...

Today
- IMPORTANT ACTION REMINDER: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm, from 4 hours ago by Accesswire
  4 hours ago by Accesswire
  Companies Mentioned: BPMC
- Stifel Adjusts Price Target on Insmed to $67 From $39, Maintains Buy Rating, from 9 hours ago by MT Newswires
  9 hours ago by MT Newswires
  Companies Mentioned: INSM
- Insmed Insider Sold Shares Worth $1,362,075, According to a Recent SEC Filing, from 15 hours ago by MT Newswires
  15 hours ago by MT Newswires
  Companies Mentioned: INSM
- Insmed Insider Sold Shares Worth $6,316,579, According to a Recent SEC Filing, from 15 hours ago by MT Newswires
  15 hours ago by MT Newswires
  Companies Mentioned: INSM
- Insmed Insider Sold Shares Worth $12,064,607, According to a Recent SEC Filing, from 15 hours ago by MT Newswires
  15 hours ago by MT Newswires
  Companies Mentioned: INSM
- Insmed Insider Sold Shares Worth $2,215,081, According to a Recent SEC Filing, from 15 hours ago by MT Newswires
  15 hours ago by MT Newswires
  Companies Mentioned: INSM
Yesterday
- Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT(R)/AYVAKYT(R) (avapritinib), from 6:01PM ET on Thursday May 30, 2024 by PR Newswire
  6:01PM ET on Thursday May 30, 2024 by PR Newswire
  Companies Mentioned: BPMC
- Insmed to Host Commercial Webinar on June 4, 2024, from 4:05PM ET on Thursday May 30, 2024 by PR Newswire
  4:05PM ET on Thursday May 30, 2024 by PR Newswire
  Companies Mentioned: INSM
- IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm, from 12:16PM ET on Thursday May 30, 2024 by Accesswire
  12:16PM ET on Thursday May 30, 2024 by Accesswire
  Companies Mentioned: BPMC
- Insmed Prices $650 Million Public Offering, from 9:58AM ET on Thursday May 30, 2024 by MT Newswires
  9:58AM ET on Thursday May 30, 2024 by MT Newswires
  Companies Mentioned: INSM

Ascendis Pharma A/S
NASDAQ:ASNDUnited States

Search Criteria

Today

European Equities Traded in US as American Depositary Receipts Rise Friday, Poised to End Week Lower, from 7 hours ago by MT Newswires

Stifel Initiates Ascendis Pharma at Buy Rating With $200 Price Target, from 9 hours ago by MT Newswires

DJ Ascendis Pharma Initiated at Buy by Stifel, from 12 hours ago by Dow Jones

Yesterday

Ascendis to Spotlight Latest Updates for TransCon(TM) Rare Endocrinology Disease Portfolio at ENDO 2024, from 8:30AM ET on Thursday May 30, 2024 by Dow Jones

May 22, 2024

European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading, from 11:01AM ET on Wednesday May 22, 2024 by MT Newswires

Peers Headlines

Today

IMPORTANT ACTION REMINDER: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm, from 4 hours ago by Accesswire

Stifel Adjusts Price Target on Insmed to $67 From $39, Maintains Buy Rating, from 9 hours ago by MT Newswires

Insmed Insider Sold Shares Worth $1,362,075, According to a Recent SEC Filing, from 15 hours ago by MT Newswires

Insmed Insider Sold Shares Worth $6,316,579, According to a Recent SEC Filing, from 15 hours ago by MT Newswires

Insmed Insider Sold Shares Worth $12,064,607, According to a Recent SEC Filing, from 15 hours ago by MT Newswires

Insmed Insider Sold Shares Worth $2,215,081, According to a Recent SEC Filing, from 15 hours ago by MT Newswires

Yesterday

Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT(R)/AYVAKYT(R) (avapritinib), from 6:01PM ET on Thursday May 30, 2024 by PR Newswire

Insmed to Host Commercial Webinar on June 4, 2024, from 4:05PM ET on Thursday May 30, 2024 by PR Newswire

IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm, from 12:16PM ET on Thursday May 30, 2024 by Accesswire

Insmed Prices $650 Million Public Offering, from 9:58AM ET on Thursday May 30, 2024 by MT Newswires